May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Topical Mitomycin C - An Effective Treatment for Ocular Surface Neoplasia
Author Affiliations & Notes
  • F. M. Dolan
    Ophthalmology-Tennent Inst, Gartnavel University Hospital, Glasgow, United Kingdom
  • E. Kemp
    Ophthalmology-Tennent Inst, Gartnavel University Hospital, Glasgow, United Kingdom
  • Footnotes
    Commercial Relationships F.M. Dolan, None; E. Kemp, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5227. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F. M. Dolan, E. Kemp; Topical Mitomycin C - An Effective Treatment for Ocular Surface Neoplasia. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5227.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: To determine the efficacy and side-effect profile of Mitomycin C 0.04% (MMC) as a treatment for ocular surface neoplasia.

Methods:: A retrospective analysis of the case notes of 38 patients treated with MMC in the last 5 years was performed and the following information obtained: demographics of the patients; clinical and histopathological diagnosis of the lesions treated; dose and side-effects of MMC used and efficacy of treatment. MMC was prescribed four times a day for 3 weeks, then 3 weeks without MMC and then a further 3 weeks of MMC four times a day. Patients were also prescribed topical lubricants and steroids four times a day for 9 weeks.

Results:: Indications for MMC were: conjunctival melanoma, primary acquired melanosis (PAM), basal, squamous and sebaceous cell carcinoma, carcinoma in situ (CIN), papilloma involving punctum, naevi and pteryguim. MMC was prescribed as a primary treatment (34.2%), as a chemotherapeutic debulking agent (26.3%) and as an adjuvant post surgery (39.5%). Transient side-effects including hyperaemia (7.9%), epiphoria (10.5%), allergic conjunctivitis (7.9%), keratopathy (5.3%), dermatitis (2.6%) and iritis (5.3%) are described, however only 3 patients (8%) required cessation of treatment due to intolerant side-effects. A favourable outcome of tumour regression was obtained in 76.3% of patients.

Conclusions:: MMC appears to be a useful and safe treatment for ocular surface neoplasia and if used with lubricant and steroid cover the side-effect profile is less than previously reported.

Keywords: oncology • drug toxicity/drug effects • conjunctiva 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.